Optimized Factor VIII Coding Sequence for rAAV Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for haemophilia A face challenges due to the large size of the human factor VIII (hFVIII) cDNA, inefficient protein expression, and the development of neutralizing antibodies, which limit the effectiveness of recombinant FVIII protein concentrates and hinder long-term treatment.
Innovation Solution
Development of an optimized nucleotide sequence encoding Factor VIII with a new promoter, specifically designed for use in rAAV vectors to enhance expression levels and stability, and a parvoviral gene delivery vector system for efficient gene transfer, aiming to achieve sustained production of functional Factor VIII protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the large size hFVIII cDNA is used for gene therapy, then the complete functional protein can be produced, but the packaging capacity of rAAV vectors is exceeded and expression efficiency decreases
Solution Approach 1:
The B-domain of the hFVIII cDNA is removed to create a truncated version that can be packaged into rAAV vectors. This extraction of the problematic large segment allows the essential functional domains to be delivered within the vector's size constraints while maintaining protein functionality.
Solution Approach 2:
The hFVIII cDNA is divided into separate domains, with the B-domain excluded and only the necessary A and C domains included in the rAAV construct. This segmentation enables efficient packaging while preserving the coagulation factor's essential functions.
2Reliability
If recombinant FVIII protein concentrates are administered frequently, then plasma FVIII levels can be maintained above 1%, but the treatment becomes prohibitively expensive and highly invasive
Solution Approach 1:
The gene therapy approach performs preliminary action by introducing the FVIII gene into patient cells, enabling endogenous production of the protein. This eliminates the need for repeated external administrations of protein concentrates, providing sustained therapeutic levels without frequent invasive interventions.
Solution Approach 2:
The patient's own cells are engineered to produce FVIII autonomously, making the system self-sustaining. The modified cells continuously synthesize and secrete functional FVIII, eliminating dependence on external protein replacements and reducing long-term treatment burden.
3Reliability
If neutralizing antibodies develop against FVIII, then the effectiveness of protein concentrates is limited, but gene therapy may overcome this by establishing endogenous production
Solution Approach 1:
The gene is introduced before neutralizing antibodies can develop, establishing endogenous FVIII production in advance. This preliminary genetic modification creates a sustainable source of FVIII that bypasses the antibody issue entirely, as the protein is produced continuously from within rather than being administered externally.
Data Source
AI summary
An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocyte biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.